| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Hannah Cohen | |
| Michael J Nash | |||
| P2860 | cites work | Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's witnesses | Q24524853 |
| A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group | Q29620037 | ||
| Treatment of life-threatening post-haemorrhagic anaemia with cell-free haemoglobin solution in an adolescent Jehovah's Witness | Q33343968 | ||
| Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits | Q33504864 | ||
| Transfusion medicine. Second of two parts--blood conservation | Q33533859 | ||
| The impact of new-variant Creutzfeldt-Jakob disease on blood transfusion practice | Q33751238 | ||
| Infected and malignant fields are an absolute contraindication to intraoperative cell salvage: fact or fiction? | Q33771272 | ||
| Viral inactivation of fresh frozen plasma | Q33992794 | ||
| Leucocyte depletion of the blood supply - how will patients benefit? | Q34022474 | ||
| Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery | Q34078012 | ||
| Blood substitutes: refocusing an elusive goal | Q34106855 | ||
| Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? | Q34164463 | ||
| Immunomodulation and blood transfusion | Q34867446 | ||
| Haematological care of the Jehovah's Witness patient | Q34929104 | ||
| Darbepoetin alfa: potential role in managing anemia in cancer patients | Q35089120 | ||
| Can children withhold consent to treatment? | Q35188222 | ||
| Reflecting on Redfern: What can we learn from the Alder Hey story? | Q35270108 | ||
| The evolution of the doctrine of consent | Q40602328 | ||
| Changes in policy of refusal of blood by Jehovah's Witnesses. Refuse and decline have distinct meanings | Q42772009 | ||
| Jehovah's Witnesses and blood transfusions | Q43077590 | ||
| Severity of anaemia and operative mortality and morbidity | Q44180563 | ||
| What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. | Q45947154 | ||
| Human cardiovascular and metabolic response to acute, severe isovolemic anemia | Q46734589 | ||
| Are women who are Jehovah's Witnesses at risk of maternal death? | Q47617491 | ||
| Combination chemotherapy with G-CSF, M-CSF and EPO: successful treatment for acute myelogenous leukemia without blood transfusion at lower medical costs | Q47738453 | ||
| Deleterious consequences of allogenic blood transfusion on postoperative infection: really a transfusion-related immunomodulation effect? | Q49278463 | ||
| Severe acute anaemia in a Jehovah's Witness. Survival without blood transfusion. | Q51797419 | ||
| The role of the court in ethical decision making. | Q51962053 | ||
| Erythropoietin to minimize perioperative blood transfusion: a systematic review of randomized trials. The International Study of Peri-operative Transfusion (ISPOT) Investigators. | Q53349241 | ||
| Erythropoietin use in a Jehovah's Witness patient. | Q53442643 | ||
| Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia. | Q53500092 | ||
| Pancreatic surgery in Jehovah's Witnesses: the role of perioperative erythropoietin and intravenous iron. | Q53501425 | ||
| Jehovah's Witnesses' blood policy. | Q53517717 | ||
| Successful treatment for acute lymphoblastic leukemia without blood transfusion in a Jehovah's Witness. | Q53559071 | ||
| Normovolemic hemodilution before cesarean hysterectomy for placenta percreta. | Q54747586 | ||
| Erythropoietin permits high-dose chemotherapy with peripheral blood stem-cell transplant for a Jehovah's Witness. | Q54762346 | ||
| A controlled trial of intra‐operative autologous transfusion in cardiothoracic surgery measuring effect on transfusion requirements and clinical outcome | Q67469333 | ||
| Are transfusions overrated? Surgical outcome of Jehovah's Witnesses | Q70555180 | ||
| Guidelines for autologous transfusion. II. Perioperative haemodilution and cell salvage. British Committee for Standards in Haematology Blood Transfusion Task Force. Autologous Transfusion Working Party | Q73493068 | ||
| Guidelines for the clinical use of red cell transfusions | Q73818776 | ||
| The prospects for red-cell substitutes | Q73837915 | ||
| Cost-effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery | Q73919754 | ||
| Treatment without consent: a medicolegal precedent | Q73990508 | ||
| Erythropoietin therapy in the perioperative setting | Q77902503 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 211-217 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Blood Reviews | Q15724415 |
| P1476 | title | Management of Jehovah's Witness patients with haematological problems | |
| P478 | volume | 18 |
Search more.